CLINICAL CHARACTERISTICS OF PATIENTS WITH DE-NOVO ACUTE MYELOID-LEUKEMIA AND ISOLATED TRISOMY-11 - A CANCER AND LEUKEMIA GROUP-B STUDY

Isolated trisomy 11 is the third most common sole trisomy in de novo a cute myeloid leukaemia (AML). However, only 49 cases have been publish ed. and for only a fraction of these cases has full description of cli nical and haematological features been provided. As a result, little i s known about the clinical characteristics of de novo AML patients wit h solitary trisomy 11. We have identified 13 patients (0.9%) with isol ated trisomy 11 among a total of 1496 consecutive adult patients succe ssfully karyotyped as part of a prospective Cancer and Leukemia Group B (CALGB) cytogenetic study (CALGB 8461), Nine patients (69%) were ove r the age of 60 (range 29-73 years). Eight patients (62%) were diagnos ed with AML of FAB M2 subtype, three patients (23%) had FAB h Il AML a nd one patient each had AML of FAB MO and M7, respectively Seven patie nts (54%) had high, >100x10(9)/1, platelet counts (median 102 x 10(9)/ 1: range 17-207 x 10(9)/1). All patients received CALGB induction ther apy with standard doses of cytarabine and daunorubicin. Six patients ( 46%) achieved a complete remission (CR). The median CR duration was 17 .5 months (range 8.7-49.8). Only one patient, who underwent bone marro w transplantation in first CR, continues in initial CR. The median sur vival was 14.3 months (range 0.5-50.7); only one patient survives. We conclude that de novo AML With isolated trisomy 11 is predominantly as sociated with older age, M2 and M1 FAB subtypes, high platelet count a nd few long-term disease-free survivals, although it is currently unkn own whether isolated trisomy 11 constitutes an independent prognostic factor.